COSCIENS Biopharma Inc.
CSCINASDAQHealthcare
$2.72
+$0.00(+0.00%)
Market Cap$8572175
P/E Ratio—
52W High$4.6054
52W Low$1.75
COSCIENS Biopharma Inc. (CSCI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CSCI · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 14, 2025EPS Actual
-$0.85
Revenue
$0.00B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 14, 2025
After Market Close
✓ 3-Quarter EPS Beat Streak
CSCI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 12, 2026 | — | — | — | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$0.85 | — | $0.00B | — | — |
| ▲ Q2 FY2025 | Apr 9, 2025 | -$3.48 | -$2.15 | +38.2% | $0.00B | $0.00B | +36.0% |
| — Q1 FY2025 | Mar 28, 2025 | — | -$4.64 | — | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$3.48 | -$1.85 | +46.8% | $0.00B | $0.00B | +72.7% |
| ▲ Q3 FY2024 | Aug 13, 2024 | -$3.28 | -$0.64 | +80.5% | $0.00B | $0.00B | +109.1% |
| ▼ Q2 FY2024 | May 14, 2024 | -$3.24 | -$4.74 | -46.3% | $0.00B | $0.00B | -99.6% |
| ▼ Q1 FY2024 | Mar 27, 2024 | -$0.97 | -$1.16 | -19.6% | $0.00B | — | — |
Q2 FY2026
May 12, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.85
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Apr 9, 2025Beat
EPS Actual
-$2.15
EPS Est.
-$3.48
EPS Surpr.
+38.2%
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025
EPS Actual
-$4.64
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$1.85
EPS Est.
-$3.48
EPS Surpr.
+46.8%
Revenue
$0.00B
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
-$0.64
EPS Est.
-$3.28
EPS Surpr.
+80.5%
Revenue
$0.00B
Q2 FY2024
May 14, 2024Miss
EPS Actual
-$4.74
EPS Est.
-$3.24
EPS Surpr.
-46.3%
Revenue
$0.00B
Q1 FY2024
Mar 27, 2024Miss
EPS Actual
-$1.16
EPS Est.
-$0.97
EPS Surpr.
-19.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-3.48 | $-3.48 | $-3.48 | 1 |
| Q3 FY2024 | $-3.48 | $-3.48 | $-3.48 | 1 |
| Q2 FY2024 | $-3.28 | $-3.28 | $-3.28 | 1 |
| Q1 FY2024 | $-3.24 | $-3.24 | $-3.24 | 1 |
| Q3 FY2023 | $-3.30 | $-3.30 | $-3.30 | 1 |
| Q2 FY2023 | $-3.48 | $-3.48 | $-3.48 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Aug 14, 2025 | — | $3.50 | $3.50 | +0.00% |
| ▲ Q2 FY2025 | Apr 9, 2025 | +38.2% | $2.45 | $2.82 | +15.10% |
| — Q1 FY2025 | Mar 28, 2025 | — | $3.08 | $3.04 | -1.30% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +46.8% | $3.34 | $3.00 | -10.18% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +80.5% | $6.31 | $6.42 | +1.74% |
| ▼ Q2 FY2024 | May 14, 2024 | -46.3% | No price data | $6.00 | — |
| ▼ Q1 FY2024 | Mar 27, 2024 | -19.6% | No price data | $6.00 | — |
| ▼ Q4 FY2023 | Nov 9, 2023 | -39.3% | No price data | $6.00 | — |
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$3.50
Price After
$3.50
Q2 FY2025+15.10%
Report Date
Apr 9, 2025
EPS Beat/Miss
+38.2%
Price Before
$2.45
Price After
$2.82
Q1 FY2025-1.30%
Report Date
Mar 28, 2025
EPS Beat/Miss
—
Price Before
$3.08
Price After
$3.04
Q4 FY2024-10.18%
Report Date
Nov 12, 2024
EPS Beat/Miss
+46.8%
Price Before
$3.34
Price After
$3.00
Q3 FY2024+1.74%
Report Date
Aug 13, 2024
EPS Beat/Miss
+80.5%
Price Before
$6.31
Price After
$6.42
Q2 FY2024—
Report Date
May 14, 2024
EPS Beat/Miss
-46.3%
Price Before
—
Price After
$6.00
Q1 FY2024—
Report Date
Mar 27, 2024
EPS Beat/Miss
-19.6%
Price Before
—
Price After
$6.00
Q4 FY2023—
Report Date
Nov 9, 2023
EPS Beat/Miss
-39.3%
Price Before
—
Price After
$6.00
Avg Beat Reaction+2.22%
Beat Rate3 / 8 quarters
Largest Move+15.10% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CSCI ends December
COSCIENS Biopharma Inc. (CSCI) most recently reported earnings on August 14, 2025 for Q3 FY2025, posting EPS of $-0.85 (in line with the analyst consensus of —). CSCI has beaten EPS estimates for 3 consecutive quarters. The next CSCI earnings date is expected around September 1, 2026.
Each quarter, investors track CSCI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CSCI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CSCI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CSCI earnings · 4 questionsCOSCIENS Biopharma Inc.'s next earnings report is expected around September 1, 2026. CSCI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CSCI historically reports after market close (AMC).
CSCI earnings datewhen is CSCI earningsCSCI next earnings datewhen does CSCI report earningsCSCI earnings calendar
▸ Source: FMP · COSCIENS Biopharma Inc. SEC filings · US GAAP · COSCIENS Biopharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026